Samsung Biologics Chooses STARLIMS
News Jun 02, 2012
Samsung is known for electronics not biotechnology, but that could change in future years as Samsung Biologics has opened a new state of the art biologics development and production facility in Incheon, Korea. To assure ongoing compliance with biologics manufacturing quality standards, Samsung BioLogics chose STARLIMS to be its LIMS provider.
“STARLIMS will provide Samsung its LIMS software to help enhance functional support for quality assurance laboratory testing and for storing and delivering analytical test results,” said Thomas Li, account manager, STARLIMS Asia Pacific. “STARLIMS passed a thorough audit and evaluation by Samsung Biologics, which demonstrates our capability to support the business needs of a world class customer operating a large contract product development and manufacturing facility.”
The new Incheon facility will develop and manufacture a wide range of biologics products through genetic engineering technologies, cell culturing and purification. By 2013, Samsung Biologics will offer a broad range of mammalian cell based, cGMP manufacturing services for cell line development, process and analytical development, clinical and commercial manufacturing, as well as aseptic fill and finish operations.
“Our biologics facility is capable of producing high quality bulk drug products. We are pleased that our quality control department is relying on STARLIMS leading edge laboratory informatics solutions to help guarantee that all process and final production are high quality, meet global regulatory standards, and maximize customer satisfaction,” said Ming fang Hong, quality control team leader, Samsung Biologics.